Phaseline

Targets › BCL2

BCL2 (Apoptosis regulator Bcl-2): drug programs, companies and trials

28 programs from 23 companies in 360 trials: 203 Phase 2, 122 Phase 1, 32 Phase 3, 3 Phase 4; Oncology, Hematology, Metabolic and endocrine; next expected readout Nov 2026.

Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. (UniProt, P10415)

Open in Phaseline: the race on BCL2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AbbVieVenetoclax
Apoptosis regulator Bcl-2 inhibitor
BCL2Phase 4Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia; Myelodysplastic Syndrome (MDS); Chronic Lymphocytic Leukemia …Nov 2026
BeOne MedicinesSonrotoclax Tablet for Oral Suspension (BGB-11417)
Bcl-2 inhibitor
BCL2Phase 3Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; CLL; Waldenstrom Macroglobulinemia …Nov 2026
Ascentage Pharma GroupApg-2575
Apoptosis regulator Bcl-2 inhibitor
BCL2Phase 3CLL/SLL; Acute Myeloid Leukemia; Higher-risk Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia …Dec 2026
AbbVieNavitoclax
Apoptosis regulator Bcl-2 inhibitor; Apoptosis regulator Bcl-X inhibitor; Apoptosis regulator Bcl-W inhibitor
BCL2, BCL2L1, BCL2L2, BCL2L2-PABPN1Phase 3Myelofibrosis (MF); Myeloproliferative Neoplasm; Mantle Cell Lymphoma Refractory; High Grade Serous Carcinoma …Dec 2026
Alliance for Clinical Trials in OncologySonrotoclax
BCL-2 inhibitor
BCL2Phase 3Chronic Lymphocytic LeukemiaSep 2028
Liping DouBCL-2 inhibitor (Zemestosita)
BCL-2 inhibitor
BCL2Phase 2R/R AMLMar 2027
Ruijin HospitalSonrotoclax (SON)
BCL2 inhibitor
BCL2Phase 2Acute Myeloid LeukemiaMay 2027
The First Affiliated Hospital of Xiamen Universityveneclax
BCL2 inhibitor
BCL2Phase 2Acute Myeloid LeukemiaJun 2027
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineBCL-2 inhibitors combined with the HyperCVAD regimen
BCL-2 inhibitor combined with HyperCVAD (hyperfractionated cyclophosphamide, doxorubicin,
BCL2Phase 2Lymphoblastic Lymphoma, AdultAug 2027
German CLL Study GroupSonrotoclax
BCL-2 inhibitor
BCL2Phase 2Richter TransformationAug 2027
BeiGeneBGB-11417 (sonrotoclax)
BCL2 inhibitor
BCL2Phase 2Leukemia; MCL; Chronic Lymphocytic Leukemia (CLL)Aug 2027
Shanghai Jiao Tong University School of Medicinesonrotoclax (BGB11417)
BCL2 inhibitor
BCL2Phase 2Acute Myeloid LeukemiaOct 2027
Guangzhou Lupeng Pharmaceutical CompanyLacutoclax (LP-108)
selective BCL-2 inhibitor
BCL2Phase 2Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Acute Myeloid LeukemiaDec 2027
Peking University People's HospitalSonrotoclax
BCL-2 inhibitor
BCL2Phase 2AL Amyloidosis (AL)Dec 2027
Massachusetts General HospitalSonrotoclax (BGB-11417)
B-cell lymphoma 2 (BCL2) protein inhibitor
BCL2Phase 2Chronic Lymphocytic LeukemiaMar 2028
Fred Hutchinson Cancer CenterSonrotoclax
BCL-2 inhibitor
BCL2Phase 2Chronic Lymphocytic LeukemiaAug 2028
Christine RyanSonrotoclax
BCL-2 protein inhibitor
BCL2Phase 2Mantle Cell LymphomaNov 2029
Canadian Cancer Trials GroupSonrotoclax
BCL-2 inhibitor
BCL2Phase 2Mantle Cell LymphomaDec 2029
Cothera BioscienceSepantronium Bromide (PC-002)
BCL2 inhibitor
BCL2Phase 2High-grade B-cell Lymphoma–
Lomond Therapeutics HoldingsLonitoclax (ZE50-0134)
BCL2 inhibitor
BCL2Phase 1Acute Myeloid Leukemia; CLL / SLLDec 2026
National Cancer Institute (NCI)Pelcitoclax
Bcl-2/Bcl-XL inhibitor
BCL2, BCL2L1Phase 1Advanced Endometrial CarcinomaFeb 2027
Bio-Path HoldingsBP1002
Bcl-2 antisense oligodeoxynucleotide
BCL2Phase 1Mantle Cell Lymphoma; Acute Myeloid Leukemia, in RelapseMar 2027
BeOne MedicinesBGB-21447
Bcl-2 inhibitor
BCL2Phase 1Hormone-receptor-positive Breast CancerJul 2027
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSonrotoclax
BCL-2 inhibitor
BCL2Phase 1Myelodysplastic Syndromes, High RiskDec 2027
Shanghai Fosun Pharmaceutical Industrial DevelopmentFXS0683
BCL-2 inhibitor
BCL2Phase 1B-Cell LymphomaAug 2028
City of Hope Medical CenterSonrotoclax
B-cell lymphoma-2 (Bcl-2) inhibitor
BCL2Phase 1Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJan 2029
Ascentage Pharma GroupAPG-3288
Dual BCL-2 and MCL-1 inhibitor
BCL2, MCL1, BCL-XLPhase 1Relapsed/Refractory Hematological MalignanciesDec 2029
Ascentage Pharma GroupAPG-1252
BCL-2 family protein inhibitor
BCL2, BCL2L1, BCL2L2, MCL1Phase 1EGFR Positive Non-small Cell Lung Cancer–

Conditions

Acute Myeloid Leukemia (73) Chronic Lymphocytic Leukemia (34) Mantle Cell Lymphoma (11) Chronic Lymphocytic Leukemia (CLL) (9) Acute Myeloid Leukemia (AML) (8) AML (7) Waldenstrom Macroglobulinemia (6) Leukemia (6) T-cell Acute Lymphoblastic Leukemia (5) Myelodysplastic Syndromes (5) CLL/SLL (5) Multiple Myeloma (4)

Modalities

small molecule (20), mixed (8)

Companies

Ascentage Pharma Group (3) Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) AbbVie (2) BeOne Medicines (2) Peking University People's Hospital (1) Bio-Path Holdings (1) Liping Dou (1) City of Hope Medical Center (1) Shanghai Jiao Tong University School of Medicine (1) BeiGene (1) Shanghai Fosun Pharmaceutical Industrial Development (1) Ruijin Hospital (1) Fred Hutchinson Cancer Center (1) National Cancer Institute (NCI) (1) The First Affiliated Hospital of Xiamen University (1) Massachusetts General Hospital (1) German CLL Study Group (1) Alliance for Clinical Trials in Oncology (1) Lomond Therapeutics Holdings (1) Guangzhou Lupeng Pharmaceutical Company (1)

Related targets

BCL2L1 (3) MCL1 (2) BCL2L2 (2) BCL-XL (1) BCL2L2-PABPN1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.